|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97显示文摘ALM To establish clone cells with different metastatic potential for the study of metastasis-related mechanisms. METHODS Cloning procedure was performed on parental hepatocellular carcinoma (HCC) cell line MHCC97. andbiological characteristics of the target clones selected by in vivo screening were studied.``RESULTS Two clones with high MHCC97-H and IowMHCC9--L1 metastatic potential were isolated from theparent cell line. Compared with MHCC97-L. MHCC97-H hadsmaller cell size average cell diameter 43 um vs 50 μmand faster in vitro and in vivo growth rate tumor celldoubling time was 34.2 h vs 60.0 h. The main ranges ofchromosomes were 5.5 58 in MHCC97-H and 57 62 inMHCC97-L. Boyden chamber in vitro invasion assay demonstrated that the number of penetrating cells through the artificial basement membrane was 137.5 - 11 .0) cellsfield for MHC_C99--H vs 17.7 - 6.3) field for MHCC97-L.The proportions of cells in GO Gl phase. S phase, and G_ M phase for MHCC97-H MHCC97-L were 0.56 6.65.0.28 0.25 and 0.l6 0.10, respectively, as measured by flow cytometry. The serum AFP levels in nude mice 5 wk after orthotopic implantation of tumor tissue were ( 24666 μg. L for MHCC97-H and (91- 66) μg' L 1 for MHCC97L. The pulmonary metastatic rate was 100% (10-10) vs40% 4- 10).``CONCLUSION Two clones of the same genetic background but with different biological behaviors were established, which could be valuable models for investigation on HCC metastasis. | Yan Li Zhao-You Tang Sheng-Long Ye Yin-Kun Liu Jie Chen Qiong Xue Jun Chen Dong-Mei Gao Wei-Hua Bao Liver Cancer Institute and Zhongshan Hospital of Fudan University (Former Liver Cancer Institute of Shanghai Medical University),Shanghai 200032,China | 2001 | World Journal of Gastroenterology2001，7，5： | 111 |
| 2 | Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein显示文摘AIM To compare the therapeutic effect andsignificances of multimodality treatment forhepatocellular carcinoma (HCC) with tumorthrombi in portal vein (PVTT).METHODS HCC patients (n = 147) with tumortrombi in the main portal vein or the first branchof portal vein were divided into four groups bythe several therapeutic methods. There wereconservative treatment group in 18 out ofpatients (group A); and hepatic artery ligation(HAL) and/or hepatic artery infusion (HAl)group in 18 patients (group B), in whompostoberative chemoembolization was doneperiodically; group of removal of HCC with PVTTin 79 (group C) and group of transcatheterhepatic arterial chemoembolization (TACE) orHAl and/or portal vein infusion (PVI) afteroperation in 32 (group D).RESULTS The median survival period was 12months in our series and the 1-, 3-, and 5-yearsurvival rates were 44.3%, 24.5% and 15.2%,respectively. The median survival times were 2,5, 12 and 16 months in group A, B, C and D,respectively. The 1-, 3- and 5-year survival rateswere 5.6%, 0% and 0% in group A; 22.2%,5.6% and 0% in group B; 53.9%, 26.9% and16.6% in group C; 79.3%, 38.9% and 26.8% ingroup D, respectively. Significant differenceappeared in the survival rates among the groups(P<0.05).CONCLUSION Hepatic resection with removalof tumor thrombi and HCC should increase thecurative effects and be encouraged for theprolongation of life span and quality of life forHCC patients with PVTT, whereas the besttherapeutic method for HCC with PVTT is withregional hepatic chemotherapy orchemoemblization after hepatic resection withremoval of tumor thrombi. | Jia Fan Zhi Quan Wu Zhao You Tang Jian Zhou Shuang Jian Qiu Zeng Chen Ma Xin Da Zhou Sheng Long Ye Liver Cancer Institute, Zhongshan Hospital, Fudan University Medical Center (Former Shanghai University), 136 Yixueyuan Road, Shanghai 200032, China | 2001 | World Journal of Gastroenterology2001，7，1： | 80 |
| 3 | Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus显示文摘Since December 2019,an epidemic caused by novel coronavirus (2019-nCoV) infection has occurred unexpectedly in China.As of 8 pm,31 January 2020,more than 20 pediatric cases have been reported in China.Of these cases,ten patients were identified in Zhejiang Province,with an age of onset ranging from 112 days to 17 years.Following the latest National recommendations for diagnosis and treatment of pneumonia caused by 2019-nCo V (the 4th edition) and current status of clinical practice in Zhejiang Province,recommendations for the diagnosis and treatment of respiratory infection caused by 2019-nCoV for children were drafted by the National Clinical Research Center for Child Health,the National Children's Regional Medical Center,Children's Hospital,Zhejiang University School of Medicine to further standardize the protocol for diagnosis and treatment of respiratory infection in children caused by 2019-nCoV. | Zhi-Min Chen Jun-Fen Fu Qiang Shu Ying-Hu Chen Chun-Zhen Hua Fu-Bang Li Ru Lin Lan-Fang Tang Tian-Lin Wang Wei Wang Ying-Shuo Wang Wei-Ze Xu Zi-Hao Yang Sheng Ye Tian-Ming Yuan Chen-Mei Zhang Yuan-Yuan Zhang | 2020 | World Journal of Pediatrics2020，16，3： | 45 |
| 4 | Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential显示文摘Metastatic human HCC model is needed for the studies on mechanism and intervention of metastatic recurrence. By using orthotopic implantation of histologically intact tissues of 30 surgical specimens, a patient like metastatic model of human HCC in nude mice (LCI-D20)and a Iow metastatic model of human HCC in nude mice LCI-D35 ) have been established. All mice with transplanted LCI-D20 tumors exhibited extremely high metastatic ability including spontaneous metastasis to liver, lungs, lymph nodes and peritoneal seeding.Remarkable difference was also found in expression of some of the invasiveness related genes and growth factors between the LCI-D20 and LCI-D35 tumors. PAI-Iincreased gradually following tumor progression in LCID20 model, and correlated with tumor size and AFP level,Phasic expression of tissue intercellular adhesion molecule-I in this model was also observed. Using corneal micropocket model, it was demonstrated that the vascular response induced by LCI-D20 tumor was stronger than that induced by LCI-D35 tumor. Similar report on metastatic human HCC model in nude mice and human HCC cell line with metastatic potential was rarely found in the literature. This LCI-D20 model has been widely used for the studies on intervention of metastasis, including antiangiogenesis, antisense approach, metalloproteinase inhibitor, differentiation inducer, etc. It is concluded that the establishment of metastatic human HCC model in nude mice and human HCC cell line with metastatic potential will provide important models for the in vivo and in vitro study of HCC invasiveness, angiogenesis as well as intervention of HCC recurrence. | Zhao-You Tang Fan-Xian Sun Jian Tian Sheng-Long Ye Yin-Kun Liu Kang-Da Liu Qiong Xue Jie Chen Jing-Lin Xia Lun-Xiu Qin Hui-Chuan Sun Lu Wang Jian Zhou Yan Li Zeng-Chen Ma Xin-Da Zhou Zhi-Quan Wu Zhi-Ying Lin Bing-Hui Yang Liver Cancer Institute of Fudan University and Zhongshan Hospital,Shanghai 200032,China | 2001 | World Journal of Gastroenterology2001，7，5： | 34 |
| 5 | Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients显示文摘Human infection with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)causes coronavirus disease 2019(COVID-19)and there is no cure currently.The 3CL protease(3CLpro)is a highly conserved protease which is indispensable for CoVs replication,and is a promising target for development of broad-spectrum antiviral drugs.In this study we investigated the anti-SARS-CoV-2 potential of Shuanghuanglian preparation,a Chinese traditional patent medicine with a long history for treating respiratory tract infection in China.We showed that either the oral liquid of Shuanghuanglian,the lyophilized powder of Shuanghuanglian for injection or their bioactive components dose-dependently inhibited SARS-CoV-23CLpro as well as the replication of SARS-CoV-2 in Vero E6 cells.Baicalin and baicalein,two ingredients of Shuanghuanglian,were characterized as the first noncovalent,nonpeptidomimetic inhibitors of SARS-CoV-23CLpro and exhibited potent antiviral activities in a cell-based system.Remarkably,the binding mode of baicalein with SARS-CoV-23CLpro determined by X-ray protein crystallography was distinctly different from those of known 3CLpro inhibitors.Baicalein was productively ensconced in the core of the substrate-binding pocket by interacting with two catalytic residues,the crucial S1/S2 subsites and the oxyanion loop,acting as a“shield”in front of the catalytic dyad to effectively prevent substrate access to the catalytic dyad within the active site.Overall,this study provides an example for exploring the in vitro potency of Chinese traditional patent medicines and effectively identifying bioactive ingredients toward a specific target,and gains evidence supporting the in vivo studies of Shuanghuanglian oral liquid as well as two natural products for COVID-19 treatment. | Hai-xia Su Sheng Yao Wen-feng Zhao Min-jun Li Jia Liu Wei-juan Shang Hang Xie Chang-qiang Ke Hang-chen Hu Mei-na Gao Kun-qian Yu Hong Liu Jing-shan Shen Wei Tang Lei-ke Zhang Geng-fu Xiao Li Ni Dao-wen Wang Jian-ping Zuo Hua-liang Jiang Fang Bai Yan Wu Yang Ye Ye-chun Xu | 2020 | Acta Pharmacologica Sinica2020，41，9： | 32 |
| 6 | Genome-wide Targeted Mutagenesis in Rice Using the CRISPR/Cas9 System显示文摘 | Lu, Yuming Ye, Xiao Guo, Renming Huang, Jing Wang, Wei Tang, Jiuyou Tan, Longtao Zhu, Jian-kang Chu, Chengcai Qian, Yangwen | 2017 | Molecular Plant2017，10，9： | 28 |
| 7 | A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy显示文摘anti-CTLA-4 抗体由阻止 B7-CTLA-4 相互作用接近否定发信号引起肿瘤拒绝,这被假定。在比临床上有效的 dosing 完成的血浆层次更加高的集中,令人惊讶地, anti-CTLA-4 抗体 Ipilimumab 不由 CTLA-4 也不 CTLA-4 绑定堵住任何一 B7 trans-endocytosis 到使不能调动或联系房间的 B7。因而, Ipilimumab 不从人性化的任何一个 CTLA4 基因在树枝状的房间(DC ) 上增加 B7 (Ctla4 h/h ) 或人的 CD34 + 茎重新组成房间的 NSG 老鼠。在 Ctla4 高效地表示人和老鼠 CTLA4 基因,绑在人的 anti-CTLA-4 抗体然而并非老鼠 CTLA-4 的 h/m 老鼠导致 Treg 弄空和 Fc 受体依赖者肿瘤拒绝。堵住的抗体 L3D10 比得上在引起肿瘤拒绝的非阻塞的 Ipilimumab。显著地,输在人类化期间堵住活动的 L3D10 子孙在导致 Treg 弄空和肿瘤拒绝仍然保持充分能干。有效地在淋巴的器官堵住 CD4 T 细胞激活和 de novo CD8 T 细胞 priming 的 Anti-B7 抗体否定地不影响 Ipilimumab 的 immunotherapeutic 效果。因此,临床上有效的 anti-CTLA-4 mAb 由独立于检查点封锁的机制引起肿瘤拒绝但是依赖于主人 Fc 受体。我们为 CTLA-4 检查点的一个重评价的数据电话封锁假设并且为安全、有效的 anti-CTLA-4 mAbs 的下一代提供新卓见。 | Xuexiang Du Fei Tang Mingyue Liu Juanjuan Su Yan Zhang Wei Wu Martin Devenport Christopher A Lazarski Peng Zhang Xu Wang Peiying Ye Changyu Wang Eugene Hwang Tinghui Zhu Ting Xu Pan Zheng Yang Liu | 2018 | Cell Research2018，28，4： | 25 |
| 8 | Relationship between expression of α-fetoprotein messenger RNA and some clinical parameters of human hepatocelular carcinoma显示文摘METHODWedetectedtheexpressionofAFPinmRNAlevelintissuesamplesfrom52patientssuferingfromHCCbyRTPCRmethod.RESULTSThepositiverat... | HE Ping, TANG Zhao You, YE Sheng Long and LIU Bin Bin | 1999 | World Journal of Gastroenterology1999，5，2： | 23 |
| 9 | Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury Issued by China Food and Drug Administration显示文摘1. Introduction Drug-induced liver injury (DILI), defined as liver injury caused by a drug and/or its metabolites, is a common clinical adverse drug reaction1–4. This type of injury can cause acute liver failure and even death in severe cases5. | Xiaohe Xiao Jianyuan Tang Yimin Mao Xiuhui Li Jiabo Wang Chenghai Liu Kewei Sun Yong’an Ye Zhengsheng Zou Cheng Peng Ling Yang Yuming Guo Zhaofang Bai Tingting He Jing Jing Fengyi Li Na An | 2019 | Acta Pharmaceutica Sinica B2019，9，3： | 22 |
| 10 | Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database显示文摘Objective:To investigate current status of diagnosis and treatment of bladder cancer in China.Methods:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were included.Data of diagnosis,treatment and pathology were collected.Results:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,respectively.Non-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,respectively.Diagnostic transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,respectively.Most MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,respectively.Three most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant chemotherapy.Conclusion:Disease characteristics are similar to international reports,while differences of diagnosis and treatment exist.This study can provide evidences for revisions of the guideline on bladder cancer in China. | Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang | 2015 | Asian Journal of Urology2015，2，2： | 21 |
| 11 | The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals显示文摘Metabolic diseases are the most common and rapidly growing health issues worldwide.The massive population-based human genetics is crucial for the precise prevention and intervention of metabolic disorders.The China Metabolic Analytics Project(ChinaMAP)is based on cohort studies across diverse regions and ethnic groups with metabolic phenotypic data in China.Here,we describe the centralized analysis of the deep whole genome sequencing data and the genetic bases of metabolic traits in 10,588 individuals from the ChinaMAP.The frequency spectrum of variants,population structure,pathogenic variants and novel genomic characteristics were analyzed.The individual genetic evaluations of Mendelian diseases,nutrition and drug metabolism,and traits of blood glucose and BMI were integrated.Our study establishes a large-scale and deep resource for the genetics of East Asians and provides opportunities for novel genetic discoveries of metabolic characteristics and disorders. | Yanan Cao Lin Li Min Xu Zhimin Feng Xiaohui Sun Jieli Lu Yu Xu Peina Du Tiange Wang Ruying Hu Zhen Ye Lixin Shi Xulei Tang Li Yan Zhengnan Gao Gang Chen Yinfei Zhang Lulu Chen Guang Ning Yufang Bi Weiqing Wang The ChinaMAP Consortium | 2020 | Cell Research2020，30，9： | 20 |
| 12 | Special Section:SARS-CoV-2 Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19显示文摘Effective therapies are urgently needed for the SARS-CoV-2 pandemic.Chloroquine has been proved to have antiviral effect against coronavirus in vitro.In this study,we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19.In this multicenter prospective observational study,we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces.Eligible patients received chloroquinephosphate s00 mg,orally,once(half dose)or twice(full dose)daily.Patients treated with non-chloroquine therapy were included as historical controls.The primary endpoint is the time to undetectable viral RNA.Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14,hospitalization time,duration of fever,and adverse events.A total of 197 patients completed chloroquine treatment,and 176patients were included as historical controls.The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine(absolute difference in medians-6.0 days;95%CI-6.0 to—4.0).The duration of fever is shorter in chloroquine(geometric mean ratio 0.6;95%CIO.5 to 0.8).No serious adverse events were observed in the chloroquine group.Patients treated with half dose experienced lower rate of adverse events than with full dose.Although randomized trials are needed for further evaluation,this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic. | Mingxing Huang Man Li Fei Xiao Pengfei Pang Jiabi Liang Tiantian Tang Shaoxuan Liu Binghui Chen Jingxian Shu Yingying You Yang Li Meiwen Tang Jianhui Zhou Guanmin Jiang Jingfen Xiang Wenxin Hong Songmei He Zhaoqin Wang Jianhua Feng Changqing Lin Yinong Ye Zhilong Wu Yaocai Li Bei Zhong Ruilin Sun Zhongsi Hong Jing Liu Huili Chen Xiaohua Wang Zhonghe Li Duanqing Pei Lin Tian Jinyu Xia Shanping Jiang Nanshan Zhong Hong Shan | 2020 | National Science Review2020，7，9： | 20 |
| 13 | Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines显示文摘AIM: To study the immunoprotective effect of liver cancer vaccine with co-transfected IL-2 and B7-1 genes on hepatocarcinogenesis in mice.METHODS: The murine liver cancer cell line Hepal-6 was transfected with IL-2 and/or B7-1 gene via recombinant adenoviral vectors and the liver cancer vaccines were prepared. C57BL/6 mice were immunized with these vaccines and challenged with the parental Hepal-6 cells afterwards.The immunoprotection was investigated and the reactive T cell line was assayed.RESULTS: The immunoprotection of the tumor vaccine was demonstrated. The effect of IL-2 and B7-1 genes cotransfected Hepal-6 liver cancer vaccine (Hep6-IL2/B7vaccine) on the onset of tumor formation was the strongest.When attacked with wild Hepal-6 cells, the median survival period of the mice immunized with Hep6-IL2/B7 vaccine was the longest (68 days, χ2=7.70-11.69, P<0.05) and the implanted tumor was the smallest (z =3.20-44.10, P<0.05).The effect of single IL-2 or B7-1 gene-transfected vaccine was next to the IL2/B7 gene co-transfected group, and the mean survival periods were 59 and 54 days, respectively.The mean survival periods of wild or enhanced green fluorescence protein gene modified vaccine immunized group were 51 and 48 days, respectively. The mice in control group all died within 38 days and the implanted tumor was the largest (z=3.20-40.21, P<0.05). The cellular immunofunction test and cytotoxicity study showed that the natural killer (NK) cell, lymphokine activated killer (LAK) cell and cytotoxic T lymphocyte (CTL) activities were significantly increased in mice immunized with the Hep6-IL2/B7 vaccine, (29.5±2.5%,65.0±2.9%, 83.1±1.5% respectively, compared with other groups, P<0.05).CONCLUSION: The Hep6-IL2/B7 liver cancer vaccines can induce the mice to produce activated and specific CTL against the parental tumor cells, and demonstrate stronger effect on the hepatocarcinogenesis than single gene modified or the regular tumor vaccine. Therefore, the vaccines may become a novel potential therapy for recurrence and metastasis of HCC. | Ning-Ling Ge Sheng-Long Ye Ning Zheng Rui-Xia Sun Yin-Kun Liu Zhao-You Tang, Liver Cancer Institute of Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China | 2003 | World Journal of Gastroenterology2003，9，10： | 19 |
| 14 | The mechanisms of sorafenib resistance in hepatocellular carcinoma:theoretical basis and therapeutic aspects显示文摘Sorafenib is a multikinase inhibitor capable of facilitating apoptosis,mitigating angiogenesis and suppressing tumor cell proliferation.In late-stage hepatocellular carcinoma(HCC),sorafenib is currently an effective first-line therapy.Unfortunately,the development of drug resistance to sorafenib is becoming increasingly common.This study aims to identify factors contributing to resistance and ways to mitigate resistance.Recent studies have shown that epigenetics,transport processes,regulated cell death,and the tumor microenvironment are involved in the development of sorafenib resistance in HCC and subsequent HCC progression.This study summarizes discoveries achieved recently in terms of the principles of sorafenib resistance and outlines approaches suitable for improving therapeutic outcomes for HCC patients. | Weiwei Tang Ziyi Chen Wenling Zhang Ye Cheng Betty Zhang Fan Wu Qian Wang Shouju Wang Dawei Rong F.P.Reiter E.N.De Toni Xuehao Wang | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 19 |
| 15 | P53 immunohistochemical scoring:an independent prognostic marker for patients after hepatocellular carcinoma resection显示文摘AIM: To confirm if p53 mutation could be a routinepredictive marker for the prognosis of hepatocellularcarcinoma (HCC) patients.METHODS: Two hundreds and forty-four formalin-fixedparaffin-embedded tumor samples of the patients with HCCreceiving liver resection were detected for nuclearaccumulation of p53. The percent of P53 immunoreactivetumor cells was scored as 0 to 3 + in P53 positive region ( <10% -, 10-30 % +, 31-50 % + +, > 50 % + + + ).Proliferating cell nuclear antigen (PCNA) and someclinicopathological characteristics, including patients' sex,preoperative serum AFP level, tumor size, capsule,vascular invasion (both visual and microscopic ), andEdmondson grade were also evaluated.RESULTS: In univariate COX harzard regression modelanalysis, tumor size, capsule status, vascular invasion,and p53 expression were independent factors that wereclosely related to the overall survival (OS) rates of HCCpatients. The survival rates of patients with 3 + for P53expression were much lower than those with 2 + or + forP53 expression. Only vascular invasion ( P < 0.05 ) andcapsule ( P < 0.01 ) were closely related to the disease-freesurvival (DFS) of HCC patients. In multivariate analysis, p53overexpression (RI 0. 5456, P < 0. 01 ) was the mostsignificant factor associated with the OS rates of patientsafter HCC resection, while tumor size (RI 0.5209, P< 0.01),vascular invasion (RI 0.5271, P < 0.01 ) and capsule (RI-0.8691, P<0.01) were also related to the OS. However, onlytumor capsular status was an independent predictive factor( P< 0.05) for the DFS. No significant prognostic value wasfound in PCNA-LI, Edmondson's grade, patients' sex andpreoperative serum AFP level.CONCLUSION: Accumulation of p53 expression, as well estumor size, capsule and vascular invasion, could bevaluable markers for predicting the prognosis of HCCpatients after resection. The quantitativeimmunohistochemical scoring for P53 nuclear accumulationmight be more valuable for predicting prognosis of patientsafter HCC resection than the common qualitative analysis. | Lun-Xiu Qin Zhao-You Tang Zeng-Chen Ma Zhi-Quan Wu Xin-Da Zhou Qing-Hai Ye Yuan Ji Li-Wen Huang Hu-Liang Jia Hui-Chuan Sun Lu Wang,Liver Cancer Institute and Zhongshan Hospital,Fudan University,Shanghai,China | 2002 | World Journal of Gastroenterology2002，8，3： | 18 |
| 16 | 粉防己碱抑制前列腺癌细胞迁移和侵袭并通过诱导凋亡抑制细胞增殖显示文摘粉防己碱作为一种传统的中药,在多种肿瘤细胞中呈现显著的抗肿瘤活性。然而,粉防己碱在前列腺癌细胞中的作用却知之甚少,且其作用于前列腺癌的具体机制也尚未有人阐述。为了探究粉防己碱对前列腺癌DU145和PC-3两种细胞系生长抑制、凋亡诱导、迁移和侵袭抑制等方面的作用,通过MTT实验和克隆形成实验检测其对前列腺癌细胞的生长抑制能力,采用流式细胞仪检测其对前列腺癌细胞的凋亡诱导作用。后通过Western blotting实验检测粉防己碱处理后两种前列腺癌细胞系中PARP、Caspase-3、Akt、p-Akt、Bcl-2、Bax等蛋白的表达情况。而细胞划痕实验和transwell侵袭实验则分别用来检测粉防己碱对前列腺癌细胞的迁移和侵袭能力。结果显示,粉防己碱可剂量依赖性和时间依赖性地抑制前列腺癌细胞系DU145和PC-3的生长;且经粉防己碱处理后,两种前列腺癌细胞系的细胞克隆数明显受到抑制。且粉防己碱可抑制两种前列腺癌细胞系的侵袭,并显著抑制其迁移能力。由此可知,粉防己碱对前列腺癌细胞的增殖、迁移和侵袭有显著抑制作用。另外,粉防己碱可剂量依赖性地诱导前列腺癌细胞的凋亡,且此过程是通过caspase级联反应的激活和PI3K-Akt信号通路的抑制而得以实现的。上述结果提示粉防己碱在临床中可作为前列腺癌治疗的一种潜在治疗药物。 | Wei Liu Bo KOU Zhen-Kun Ma Xiao-Shuang Tang Chuan Lv Min Ye Jia-Qi Chen Lei Li Xin-Yang Wang Da-Lin He | 2015 | Asian Journal of Andrology2015，17，5： | 18 |
| 17 | Advanced Space-based Solar Observatory(ASO-S):an overview显示文摘The Advanced Space-based Solar Observatory(ASO-S)is a mission proposed for the 25 th solar maximum by the Chinese solar community.The scientific objectives are to study the relationships between the solar magnetic field,solar flares and coronal mass ejections(CMEs).Three payloads are deployed:the Full-disk vector Magneto Graph(FMG),the Lyman-αSolar Telescope(LST)and the Hard X-ray Imager(HXI).ASO-S will perform the first simultaneous observations of the photospheric vector magnetic field,non-thermal imaging of solar flares,and the initiation and early propagation of CMEs on a single platform.ASO-S is scheduled to be launched into a 720 km Sun-synchronous orbit in 2022.This paper presents an overview of the mission till the end of Phase-B and the beginning of Phase-C. | Wei-Qun Gan Cheng Zhu Yuan-Yong Deng Hui Li Yang Su Hai-Ying Zhang Bo Chen Zhe Zhang Jian Wu Lei Deng Yu Huang Jian-Feng Yang Ji-Jun Cui Jin Chang Chi Wang Ji Wu Zeng-Shan Yin Wen Chen Cheng Fang Yi-Hua Yan Jun Lin Wei-Ming Xiong Bin Chen Hai-Chao Bao Cai-Xia Cao Yan-Ping Bai Tao Wang Bing-Long Chen Xin-Yu Li Ye Zhang Li Feng Jiang-Tao Su Ying Li Wei Chen You-Ping Li Ying-Na Su Hai-Yan Wu Mei Gu Lei Huang Xue-Jun Tang | 2019 | Research in Astronomy and Astrophysics2019，19，11： | 17 |
| 18 | Consensus on the application of negative pressure wound therapy of diabetic foot wounds显示文摘Because China is becoming an aging society,the incidence of diabetes and diabetic foot have been increasing.Diabetic foot has become one of the main health-related killers due to its high disability and mortality rates.Negative pressure wound therapy(NPWT)is one of the most effective techniques for the treatment of diabetic foot wounds and great progress,both in terms of research and its clinical application,has been made in the last 20 years of its development.However,due to the complex pathogenesis and management of diabetic foot,irregular application of NPWT often leads to complications,such as infection,bleeding and necrosis,that seriously affect its treatment outcomes.In 2020,under the leadership of Burns,Trauma and Tissue Repair Committee of the Cross-Straits Medicine Exchange Association,the writing group for‘Consensus on the application of negative pressure wound therapy of diabetic foot wounds’was established with the participation of scholars from the specialized areas of burns,endocrinology,vascular surgery,orthopedics and wound repair.Drawing on evidence-based practice suggested by the latest clinical research,this consensus proposes the best clinical practice guidelines for the application and prognostic evaluation of NPWT for diabetic foot.The consensus aims to support the formation of standardized treatment schemes that clinicians can refer to when treating cases of diabetic foot. | Shizhao Ji Xiaobin Liu Jie Huang Junmin Bao Zhaohong Chen Chunmao Han Daifeng Hao Jingsong Hong Dahai Hu Yufeng Jiang Shang Ju Hongye Li Zongyu Li Guangping Liang Yan Liu Gaoxing Luo Guozhong Lv Xingwu Ran Zhongmin Shi Juyu Tang Aiping Wang Guangyi Wang Jiangning Wang Xin Wang Bing Wen Jun Wu Hailin Xu Maojin Xu Xiaofei Ye Liangxi Yuan Yi Zhang Shichu Xiao Zhaofan Xia | 2021 | Burns & Trauma2021，9，1： | 17 |
| 19 | Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor显示文摘According to the World Health Organization(WHO)newly updated situation report on March 18th,2020,the coronavirus disease 2019(COVID-19)pandemic has confirmed 191,127 cases and claimed 7807 deaths worldwide.1 The etiological agent of COVID-19 has been identified as a novel coronavirus,the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),belonging to Sarbecovirus subgenus(genus Betacoronavirus,family Coronaviridae)and showing 79.6 and 96.2%sequence identity in nucleotide to SARS-CoV and a bat coronavirus(BatCoV RaTG13),respectively.2–4 Like SARS-CoV infection,a substantial fraction of COVID-19 patients exhibits severe respiratory symptoms and has to be hospitalized in intensive care unit.5–8 Although the mortality rate of COVID-19 is significantly lower than that of SARS-CoV infection,SARS-CoV-2 shows much higher human-to-human transmission rate,rapidly leading to a global pandemic declared by WHO on March 11th,2020. | Xiangyu Chen Ren Li Zhiwei Pan Chunfang Qian Yang Yang Renrong You Jing Zhao Pinghuang Liu Leiqiong Gao Zhirong Li Qizhao Huang Lifan Xu Jianfang Tang Qin Tian Wei Yao Li Hu Xiaofeng Yan Xinyuan Zhou Yuzhang Wu Kai Deng Zheng Zhang Zhaohui Qian Yaokai Chen Lilin Ye | 2020 | Cellular & Molecular Immunology2020，17，6： | 17 |
| 20 | Recurrent gain-of-function USP8 mutations in Cushing's disease显示文摘库欣的疾病,引起过量皮质醇生产的也已知的同样促肾上腺皮质的荷尔蒙(ACTH )-secreting 垂体腺瘤(舞步) ,占多达 85%corticotrophin 依赖的库欣的症候群盒子。然而,在这疾病的基因改变是不清楚的。这里,我们执行了从 12 秘密 ACTH 舞步导出并且匹配血样品的 DNA 定序的 whole-exome,它在候选人基因揭示了体的变化的三种类型, USP8 (编码 ubiquitin 特定的朊酶 8 ) ,专门在 exon 14 在 12 秘密 ACTH 舞步中的 8 个。我们进一步评估了体的 USP8 变化在另外由定序的 Sanger 的 258 舞步。进一步定序指向在 108 秘密 ACTH 舞步(62.04%) 中的 67 个识别了 USP8 变体的 17 种类型的一个总数。然而,任何一个都没在舞步的另外的类型这些变化被检测(n = 150 ) 。这些变化在 USP8 的 14-3-3 绑定主题以内聚集并且破坏在 USP8 和 14-3-3 蛋白质之间的相互作用,导致保护 EGFR 免受 lysosomal 降级的伤害的一个提高的能力。因此,有 EGFR 表示,提高的 EGFR 蛋白质丰富和 mRNA 表示的更高的发生 POMC 铺平的变异的 USP8 显示的舞步,它编码 ACTH 的先锋。有变异的 USP8 的舞步在尺寸是显著地更小的并且比野类型的舞步有更高的 ACTH 生产。在里面通过手术 resected 主要变异 USP8 的肿瘤房间, USP8 击倒或堵住的 EGFR 有效地稀释 ACTH 分泌物。一起拿,体的 gain-of-function USP8 变化是普通的并且在库欣的疾病贡献 ACTH 生产过剩。USP8 或 EGFR 的抑制为对待变异 USP8 的 corticotrophin 腺瘤是有希望的。我们的学习在库欣的疾病加亮潜在地功能的变异的基因并且提供卓见进这疾病的治疗学。 | Zeng-Yi Ma Zhi-Jian Song Jian-Hua Chen Yong-Fei Wang Shi-Qi Li Liang-Fu Zhou Ying Mao Yi-Ming Li Rong-Gui Hu Zhao-Yun Zhang Hong-Ying Ye Ming Shen Xue-Fei Shou Zhi-Qiang Li Hong Peng Qing-Zhong Wang Dai-Zhan Zhou Xiao-Lan Qin Jue Ji Jie Zheng Hong Chen Yin Wang Dao-Ying Geng Wei-Jun Tang Chao-Wei Fu Zhi-Feng Shi Yi-Chao Zhang Zhao Ye Wen-Qiang He Qi-Lin Zhang Qi-Sheng Tang Rong Xie Jia-Wei Shen Zu-Jia Wen Juan Zhou Tao Wang Shan Huang Hui-Jia Qiu Ni-Dan Qiao Yi Zhang Li Pan Wei-Min Bao Ying-Chao Liu Chuan-Xin Huang Yong-Yong Shi Yao Zhao | 2015 | Cell Research2015，25，3： | 16 |
您所在的机构暂未开通此部分的功能，请联系管理员